Clinical trial · Interventional
The Oral Microbiome in OSCC
The Oral Microbiome in Oral Squamous Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Previous work by a number of scientific teams has revealed that the types of bacteria that colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The purpose of this study is to investigate the extent of these changes and to correlate the changes with alterations in the activities of the host's own oral tissues. In doing so, we believe we can gain a better understanding of how particular bacterial species, or consortia of species, can result in an individual having an increased risk of the most common type of oral cancer -- oral squamous cell carcinoma. This knowledge may also lead to the identification of salivary biomarkers that can be used for clinical evaluation or screening. In addition, we seek to determine the extent to which a probiotic regimen can help prevent or rectify the disease-related changes in the types of bacterial colonizing the mouth. The microbiome in health, pre-cancerous lesions, and cancerous lesions will be determined from remnant microbial DNA in banked tissue samples. The effects of probiotics on the oral microbiome will be determined from DNA collected from swabs of oral tissue at baseline and then after 3 to 6 months of probiotic usage.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Cancer | Malignant Lip and Oral Cavity Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Placebo Lozenge | Other | — | UNRESOLVED |
| ProDentis Lozenge | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Probiotic Lozenge
- interventionNames
- Dietary Supplement: ProDentis Lozenge
- type
- PLACEBO_COMPARATOR
- label
- Placebo Lozenge
- interventionNames
- Other: Placebo Lozenge
Primary outcomes (2)
- measure
- Assessment of changes in the oral microbiome composition over time
- timeFrame
- Up to 3 months
- description
- 16S Genomic Profiling will be done in all recruited subjects via oral swab of pre-cancerous or cancerous oral lesion
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 89 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adults (21-70 years old) who have been diagnosed with oral dysplasia or that have been treatment-planned as wait and watch or 2. Adults (21-70 years old) or who have been diagnosed with oral squamous cell carcinoma, or matched healthy controls free of any oral lesions Exclusion Criteria: 1. Adults who have had a course of antibiotics that was completed less than 3 months prior to the study; 2. Adults with any immunosuppressive condition or medication that would put the subject at risk of consuming daily probiotics; 3. Adults who regularly use probiotic dietary supplements 4. Adults that have alcohol/tobacco use history that does not match study population - this if for the healthy controls arm only.
References
Publications (0)
Data not yet available